A tennis lesson: sharp practice in the science behind the Sharapova case
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Maria Sharapova (and hundreds of other elite athletes) took meldonium, a drug developed at the time of the USSR for the treatment of heart attack and stroke, though it has never been approved for use anywhere outside of the former Soviet Union. Meldonium is an inhibitor of γ-butyrobetaine hydroxylase, an enzyme involved in the carnitine biosynthetic pathway.1 Intake results in a reduction of tissue carnitine content, including the heart and skeletal muscles. Carnitine plays a critical role in transferring long-chain fatty acids across mitochondrial inner membrane into the mitochondrial matrix, to enable entry of the fatty acid moiety into the oxidation pathway, to synthesise ATP aerobically.2 In cases when intracellular carnitine availability is compromised, such as in neonatal primary carnitine deficiency,3 those affected experience hypoglycaemia, fatigue, seizures and cardiomyopathy.3 Carnitine-deficient individuals are sensitive to prodrugs containing the pivaloyl moiety, as pivalic acid is a prodrug able to induce carnitine deficiency (like meldonium); this results in lethal cardiac arrhythmias.4 Meldonium administered orally at ‘recommended’ doses (500 mg, twice daily)5 would not have such a drastic effect. However, even a moderate reduction of muscle carnitine content in healthy volunteers treated with pivaloyl-conjugated antibiotics for 54 days reduces work at maximal oxygen uptake (VO2max), maximal heart rate,6 reduced interventricular septum thickness and left ventricular mass.7 The oral administration of meldonium to healthy volunteers (500 mg, twice daily) for 4 weeks leads to a significant 18% reduction of plasma carnitine.5 Even though we are not aware of the meldonium dosage prescribed to Ms Sharapova, it is safe to assume that, in the absence of oral carnitine supplementation, her muscle carnitine content would have been, at most, only modestly decreased, and would have resulted in a minimal impact on her muscle oxidative capacity, as evidenced by her continued performance at the highest levels in her sport. The medical team looking after Ms Sharapova appears to have confounded the tangible beneficial effects of depressing acylcarnitine formation in ischaemic heart (which may improve glucose use, eg, during ischaemia–reperfusion) with the requirement of normal cardiac muscle for high rates of carnitine-dependent fatty acid oxidation. A recent study in rodents has shown that even a moderate, silent carnitine-deficient phenotype may reveal its fragility when subjected to strong adrenergic stress.8 Therefore, unless meldonium has unidentified off-target pharmacological effects, one has to be thankful that it was not administered in high enough doses so as to damage the athletes who continued to take it. Another aspect of meldonium pharmacology is the inhibition of carnitine acetyltransferase (CAT) activity,9 an enzyme that reversibly transfers the acetyl moiety of acetyl coenzyme A to carnitine in mitochondria and peroxisomes. Due to its capacity to buffer mitochondrial acetyl coenzyme A levels, CAT plays a prominent role in intermediary metabolism and muscle bioenergetics.2 As expected, in rodent models, a lowered muscle CAT activity results in muscle fatigue and exercise intolerance.10 This would again strongly argue against the use of meldonium as a performance-enhancing drug, particularly if such CAT-inhibitory activity is combined with carnitine depletion. The World Anti-Doping Agency (WADA) may have decided to add meldonium to the Prohibited List, not necessarily because of any illusory performance-enhancing action in healthy athletes, but because of the real danger that it carries for the overenthusiastic athlete who may overdose on it and lower intracellular carnitine to pathological levels. A comprehensive literature search of several databases failed to unearth any cogent evidence of the potential meldonium effect in enhancing physical performance in healthy subjects, with only one clinical trial conducted on a small cohort of old (average >60 year) patients with angina pectoris, to evaluate exercise tolerance. On such minimal findings is the dangerous extrapolation to an assumed performance-enhancing effect of meldonium in healthy elite athletes based. It is not an overstatement to emphasise that the understanding of metabolism is a postmodernist discipline in which neither the inadequately trained scientists (Metabolism is a Cinderella subject in most universities) nor the editors of journals or the clinicians who peruse their publications know how to interpret the intricacies of control in metabolism. This is an era in which metabolic science is overrun by overemphasis on gross changes in gene expression, and too little on the reductionist discipline of the study of the function of proteins, their interactions, and their effects on metabolic fluxes. Athletes chasing the shadows of marginal gains are the unwitting victims. Hats off to WADA who may have recognised that, even in the ab
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We can note only two works published in English re- garding the possible ability of meldonium to enhance athletic performance, one of which is a narrative review (28,29).”
From The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review (2021) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disorders of carnitine transport and the carnitine cycle
Longo, N., Amat di San Filippo, C., & Pasquali, M. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30087 · Cited by 543
Carnitine, mitochondrial function and therapy
Zammit, V. A., Ramsay, R. R., Bonomini, M., & Arduini, A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.024 · Cited by 149
Self-citationSimkhovich, B. Z., SHUTENKO, Z., Meirēna, D. V., Khagi, K. B., Mezhapuke, R., Tn, M., Kalvlņš, I. J., & Lukevics, E. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90717-4 · Cited by 112
Carnitine Acetyltransferase Mitigates Metabolic Inertia and Muscle Fatigue during Exercise
Seiler, S. E., Koves, T. R., Gooding, J. R., Wong, K. E., Stevens, R. D., Ilkayeva, O. R., Wittmann, A. H., DeBalsi, K. L., Davies, M. N., Lindeboom, L., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.003 · Cited by 105
Rasmussen, J., Nielsen, O. W., Lund, A. M., Køber, L., & Djurhuus, H. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9488-8 · Cited by 64
Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism
Jaudzems, K., Kuka, J., Gutsaits, A., Zinovjev, K., Kalvinsh, I., Liepinsh, E., Liepinsh, E., & Dambrova, M. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360902829527 · Cited by 50
Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers
Liepinsh, E., Konrade, I., Skapare, E., Pugovics, O., Grinberga, S., Kuka, J., Kalvinsh, I., & Dambrova, M. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01325.x · Cited by 47
Abrahamsson, K., Mellander, M., Eriksson, B. O., Holme, E., Jodal, U., Jonsson, A., & Lindstedt, S. (1995) · Heart · doi:10.1136/hrt.74.6.656 · Cited by 30
Pivalic acid-induced carnitine deficiency and physical exercise in humans
Abrahamsson, K., Eriksson, B. O., Holme, E., Jodal, U., Jönsson, A., & Lindstedt, S. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90179-1 · Cited by 18
A Moderate Carnitine Deficiency Exacerbates Isoproterenol-Induced Myocardial Injury in Rats
Giudice, P. L., Bonomini, M., & Arduini, A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6647-4 · Cited by 14
Self-citation
Cited by
Metabolic Flexibility in Health and Disease
Goodpaster, B. H., & Sparks, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.015 · Cited by 995
“…well-publicized use of Melondrate, which has been used by some countries (not approved in the United States) to inhibit fatty acid oxidation through decreases in carnitine palmitoyl transferase (CPT), in order to treat cardiac dysfunction and impaired cardiac metabolism (Arduini and Zammit, 2016).”
Cristo, F. D., Finicelli, M., Digilio, F. A., Paladino, S., Valentino, A., Scialò, F., D’Apolito, M., Saturnino, C., Galderisi, U., Giordano, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27602 · Cited by 43
“…on the WADA’s Prohibited List did not mention any safety concerns, some authors have also questioned about the safety of meldonium in humans (Arduini & Zammit, 2016), Thus, more in vivo studies are needed not only to confirm the effects of meldonium on different animal models but in…”
BackgroundBezuglov, E., Talibov, O., Butovskiy, M., Khaitin, V., Achkasov, E., Waśkiewicz, Z., & Lazarev, A. (2021) · Asian Journal of Sports Medicine · doi:10.5812/asjsm.110753 · Cited by 26
“garding the possible ability of meldonium to enhance athletic performance, one of which is a narrative review (28, 29).”
BackgroundMeldonium: Pharmacological, toxicological, and analytical aspects
Berlato, D. G., & de Bairros, A. V. (2020) · Toxicology Research and Application · doi:10.1177/2397847320915143 · Cited by 33
“Since its prohibition from sporting events, there have been several doping cases that involve meldonium, especially for Eastern European athletes.(7,8) According to the WADA,(9) meldonium was added (to the Prohibited List) because of evidence of its use by athletes with the intention of enhancing performance.”
BackgroundAnnual banned‐substance review: analytical approaches in human sports drug testing
Thevis, M., Kuuranne, T., Geyer, H., & Schänzer, W. (2016) · Drug Testing and Analysis · doi:10.1002/dta.2139 · Cited by 24
Metadata
- Authors
- Arduini, A., & Zammit, V. A.
- Affiliations
- CoreQuest (Switzerland) (CH)
- University of Warwick (GB)
- Corresponding author
- Zammit, Victor A
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-01
- Volume
- 92
- Issue
- 1090
- Pages
- 429-430
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- PMC
- PMC4975811
- OpenAlex
- W2409595189
- Cited by
- 16
- References
- 10
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Postgraduate Medical Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Social Sciences › Sociology and Political Science › Doping in Sports
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- meldonium, doping, carnitine deficiency, gamma-butyrobetaine hydroxylase, carnitine biosynthesis, fatty acid oxidation, mitochondrial function, primary carnitine deficiency, cardiac arrhythmias, elite athletes, VO2max, ischemic heart disease
- MeSH terms
- Cardiovascular Agents, Carnitine, Doping in Sports, Female, Heart, Humans, Methylhydrazines, Tennis, Muscle, Skeletal, Athletes, Performance-Enhancing Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A tennis lesson: sharp practice in the science behind the Sharapova case. https://app.cochat.ai/papers/10.1136/postgradmedj-2016-134124
- The paper
- Arduini, A., & Zammit, V. A. (2016). A tennis lesson: sharp practice in the science behind the Sharapova case. Postgraduate Medical Journal. https://doi.org/10.1136/postgradmedj-2016-134124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.